Open Access

Anaphylactic reactions presenting with hypertension

  • Emrullah Solmazgul1,
  • Ali Kutlu2,
  • Salim Dogru3,
  • Veysel Ozalper4,
  • Ibrahim Cetindagli5Email author,
  • Ogun Sezer6,
  • Musa Salmanoglu1,
  • Erol Kilic7,
  • Ercan Karabacak8 and
  • Sami Ozturk2
SpringerPlus20165:1223

https://doi.org/10.1186/s40064-016-2913-y

Received: 4 March 2016

Accepted: 26 July 2016

Published: 2 August 2016

Abstract

Background

Although a few case reports about hypertensive anaphylaxis (HA) are available in the present literature, there is no study about the prevalence of HA. In this study, we review our cases with anaphylaxis presenting with hypertension and ascertain its prevalence. The documents of the patients who had anaphylactic reactions after the procedures performed for the diagnosis and treatment of allergic diseases in GATA Haydarpasa Clinic of Allergy and Immunology between January 2010 and December 2014 were retrospectively reviewed. Within the study period, 324 patients had undergone 4332 procedures in which 62 of them had developed anaphylaxis.

Results

During the procedures, the rate of anaphylaxis was found to be 1.43 %. The rate of HA among the anaphylaxis patients was 12.9 % (8 of 62 patients). During treatments, 2 patients received adrenaline injections without any adverse reaction.

Conclusions

HA may be seen at a considerable rate during an anaphylactic reaction. Anaphylaxis and hypertension can be recovered by adrenaline injection when required. According to the best of our knowledge, this study is the first original study about the prevalence of HA in English-language medical literature.

Keywords

Anaphylactic reactionsHypertensionPrevalenceAdrenaline

Background

Anaphylaxis is an acute, potentially life-threatening systemic allergic reaction which has a particular importance to all health-care professionals. Diagnosis of anaphylaxis is usually based on the history of allergen exposure and physical findings (Sampson et al. 2006; Simons 2010).

Anaphylactic reactions like airway, breathing and circulatory problems are not always associated with skin and mucosal changes. Other than the upper airway obstruction, cardiovascular collapse is the second most life-threatening anaphylactic reaction which requires an urgent treatment. Reduced blood pressure after exposure is known to be the leading indicator of anaphylactic reaction (Muraro et al. 2014).

Hypotension is the most common cardiovascular system finding and considered to be a criterion for diagnosis of anaphylaxis. Nonetheless, we hypothesize that hypertension can also be encountered in anaphylactic reactions due to compensatory vasopressor responses. Although there are a few case reports in literature, no study about the prevalence of hypertensive anaphylaxis (HA) has been reported. In this study, we analyzed our cases with anaphylaxis who presented with hypertension in order to ascertain the prevalence of HA.

Methods

The documents of the patients who had anaphylactic reactions after the procedures performed for the diagnosis and treatment of allergic diseases in GATA Haydarpasa Clinic of Allergy and Immunology between January 2010 and December 2014 were retrospectively reviewed. The procedures causing anaphylactic reactions were allergen immunotherapy, allergy provocation tests (medication, food, physical urticaria, exercises) and allergic skin tests.

Before all the procedures, a follow-up form has been created. Information about medical histories of the patients were obtained, vital signs were measured and recorded to the follow-up form. First blood pressure value measured was regarded as the basal blood pressure. Patient’s blood pressure was recorded and evaluated according to the instructions mentioned in Eighth Joint National Committee Guideline (James et al. 2013). Patients who had been previously diagnosed with hypertension, treated for hypertension or measured hypertensive as basal blood pressure were excluded from the study. Patients with any previous diagnosis of multiple drug intolerance syndrome, neuropsychiatric diseases (anxiety, panic disorder, psychogenic dyspnea, dissociative disorder, globus hystericus, conversion) were also excluded from the study. Clinical criteria for diagnosing anaphylaxis were based on The European Academy of Allergy and Clinical Immunology (EAACI) 2014 Guideline (Muraro et al. 2014). Following initial symptoms of anaphylaxis, patients those with the arterial tension of over 140/90 mmHg were considered to have a hypertensive anaphylactic reaction (James et al. 2013).

For patients who were interfered with the diagnosis of hypertensive anaphylactic reaction, the factors causing anaphylactic reaction, symptoms, arterial blood pressure (BP) measurements and the treatments performed were all noted and evaluated. After the symptoms decreased, the patients were kept under observation, vital signs were monitored hourly for 6 h.

The local ethics committee approved the study protocol and written informed consent was obtained from all participants.

Results

Within the study period, 324 patients had undergone 4332 procedures in which 62 of them had developed anaphylaxis. During these procedures, the rate of anaphylaxis was found to be 1.43 %. Eight patients with HA fitted the criteria mentioned above (4 females, 4 males). The rate of HA among the anaphylaxis patients was 12.9 % (Table 1). The mean age of HA patients was 25.8 years. Among HA patients, two had anaphylactic reaction following bee venom administration (1 patient received vespula venom, 1 patient received Apis mellifera therapy), one had anaphylactic reaction following fresh prick test with multi-foods, four had anaphylaxis following house dust mite (HDM) mixture administration, and one had anaphylactic reaction after the application of omalizumab (Table 2). Reactions developed in the course of the increasing dose application in 1 patient who received a bee venom immunotherapy and in 2 patients who received a HDM immunotherapy.
Table 1

Patients tested or treated for allergy and prevalence of anaphylaxis

Immunotherapy—test type

Mean age (years)

Number of patients

Number of procedures

Number of total anaphylaxis/procedures (%)

Hypertensive anaphylaxis/total anaphylaxis (%)

Bee-venom

33

25

569

15/569 (2.63)

2/15 (13.33)

Food-drug provocation test

42

36

101

32/101 (3.12)

1/32 (3.12)

Inhalen Allergen IT (immunotherapy)

27.7

177

3194

14/3194 (0.43)

4/14 (28.57)

Drug Injection (Omalizumab)

44

86

468

1/468 (0.21)

1/1 (100)

Total

36

324

4332

62/4332 (1.43)

8/62 (12.90)

Table 2

Patients who developed hypertensive anaphylaxis and their managements

Case number

Sex/age (years)

Allergic disease

Causes of anaphylaxis

Additional symptomsa

ABP after anaphylaxisb (mmHg)

Treatment

1.

M/20

Bee venom allergy

Venom immunotherapy (vespula 100 mcg)

Papular urticarial lesions

170/100

ivAH, ivSt, nBD

2.

M/20

Bee venom allergy

Venom immunotherapy (Apis mellifera 80 mcg)

 

220/150

ivAH, ivSt, nBD

3.

M/20

Anaphylaxis with multiple food

Prick test with multiple fresh food

Dyspnea, generalize edema

190/120

ivAH, ivSt, nBD

4.

M/37

Allergic rhinitis

Immunotherapy with HDM mix (100.000 SQ-U/ml 0.5 cc)

 

170/110

ivAH, ivSt, nBD

5.

F/19

Asthma and allergic rhinitis

Immunotherapy with HDM mix (10 IR/ml 0.2 cc)

Wheezing

150/90

ivAH, imE, nBD

6.

F/39

Asthma and allergic rhinitis

Immunotherapy with HDM mix (10 IR/ml 1 cc)

Papular urticarial lesions

150/90

ivAH, ivSt, nBD, ACEi

7.

F/29

Asthma and allergic rhinitis

Immunotherapy with Phostal 350 (1 ml)

Papular urticarial lesions

160/100

ivAH, ivSt, nBD, ACEi

8.

F/23

Multiple drug, food and latex allergy, chronic urticaria, angioedema

Omalizumab treatment (300 mg/month)

Difficulty in breathing, tachycardia

150/100

ivAH, scE, imE, nE, ACEi

M male, F female, ABP arterial blood pressure, HDM house dust mite, ivAH IV antihistaminic, ivSt IV steroid, scE Subcutaneus Epinephrine, imE IM Epinephrine, nBD nebulized bronchodilator, nE nebulized epinephrine, ACEi angiotensin converting enzyme inhibitor

aClassical initial anaphylactic symptoms (generalized itching, flushing, swelling of the lips and skin, urticaria) are not mentioned here

bAll patients basal blood pressures were normotensive

Following the HA reaction, and just before the initiation of anaphylaxis treatment, the systolic and diastolic BPs were measured, and were expected to be between 150 and 220 mmHg versus 90 and 150 mmHg, respectively, to be considered as HA. During treatment, 2 patients received epinephrine injections (one had additional nebulized epinephrine) without any complication. The BPs of patients who had received epinephrine were 150/90 and 150/100 mmHg, respectively. The symptoms of all patients recovered within minutes (1–10 min) following treatments.

We performed a 4-day-rush protocol on 2 of our patients (patients numbered 1 and 2) who had developed an anaphylaxis due to venom immunotherapy. One of these patients had developed a monthly maintenance level, while the other one had an initial build-up phase anaphylaxis. One patient who had received an immunotherapy due to HDM had a monthly maintenance level, whereas two patients had developed an initial build-up phase anaphylaxis (patients numbered 4, 5 and 6). Three of the patients who had anaphylaxis during the immunotherapy had also developed papular urticarial lesions during reaction (patients numbered 1, 6, and 7).

One patient (patient numbered 8) who had been diagnosed with multiple drug, food and latex allergy and receiving omalizumab injections for chronic urticaria and angioedema had anaphylactic reaction in 2nd year of treatment. Upon the start of this patient’s complaints, 0.5 mg of subcutaneous epinephrine and nebulized epinephrine was administered. Following this procedure, arterial BP was increased to 180/100 from 150/100 mmHg. Since the increased complaints indicating an upper airway obstruction, intramuscular 0.3 mg epinephrine was also administered. Then, the complaints resolved and high BP was normalized. The patient had received this treatment several times without experiencing any allergic reaction until the occurrence of anaphylaxis.

One patient (patient numbered 3) who was thought to have multiple food allergies, developed HA during fresh prick testing (prick to prick). This patient had a medical history of anaphylactic reactions (common body rash and erythema, swelling of the lips, dyspnea) following food intake a couple of times. No reaction was observed in the skin prick test performed commercially along with the ready-made food allergy test panel. On follow-up, this patient revealed that he had been experiencing new allergic reactions through various fruits which he had once eaten without a problem. He stated that he was having common rash and erythema on his body along with dyspnea after he ate apricot, plums and cherries at different times. He also stated that these complaints were accompanied by a blackout, palpitation and sort of a coma after he ate peach. A fresh prick testing was performed on the patient by administration of an apricot, a peach and a plum. An edema reaction was observed which was accompanied by erythemas with the sizes of 7 × 8 mm, 5 × 6 mm, 6 × 6 mm after peach, apricot and plum intake, respectively. Following this test, a severe anaphylaxis had developed within 10 min. He was then relieved with the administration of antihistaminic, steroid and nebulized bronchodilator therapy.

In patients with hypertensive anaphylactic reaction, the blood pressure returned to normal values with regression of the other symptoms. Despite the observed improvement, the patients were kept under observation and vital signs were monitored hourly for 6 h.

Discussion

Anaphylaxis has an acute and unexpected onset; it may vary in severity and may resolve spontaneously. The clinical manifestations of anaphylaxis depend on the organ systems involved. Onset of symptoms, clinical severity, and sequence of symptom progression varies between individuals, and reactions may even vary in the same individual between episodes (Järvinen and Celestin 2014). Widely accepted criteria to help clinicians identify possible anaphylaxis emphasize the rapid onset of its multiple symptoms and signs (Sampson et al. 2006). Reduced blood pressure after exposure to an allergen (for adults: systolic blood pressure of <90 mmHg or >30 % decrease from that individual’s baseline) is the leading indicator of an anaphylactic reaction (Muraro et al. 2014). However, our results revealed that the prevalence of HA may be at a considerable rate (12.90 %), thus, hypotension may not be a standard symptom of anaphylactic reaction.

Among other symptoms of anaphylaxis, cutaneous manifestations occur in most cases, but it may develop without skin changes (Muraro et al. 2014). Respiratory or cardiovascular symptoms are the potentially life-threatening features of anaphylaxis (Simons et al. 2012). Respiratory symptoms occur more frequently in children, and cardiovascular symptoms predominate in adults (Muraro et al. 2014). In our cases, respiratory and cardiovascular symptoms were more prominent, which may be probably due to earlier ages of the patients.

During an anaphylactic reaction, immediate release of a series of mediators, including histamines, leukotrienes, prostaglandins, thromboxanes, and bradykinins from basophils and mast cells cause increased mucous membrane secretions, increased capillary permeability and leak, markedly reduced smooth muscle tone in blood vessels (vasodilation) and bronchioles, and bronchial smooth muscle contractions (Ecc Committee S, Task Forces of the American Heart A 2005). Internal compensatory vasopressor responses such as secretion of catecholamines, activation of angiotensin system, production of potent vasoconstrictor peptide endothelin-1 may induce unsteady reactions and in some patients, peripheral resistance can increase to abnormally high levels during anaphylactic episodes. Serotonin has an important role in the mechanism of anaphylaxis which may also lead to systemic hypertension over the receptors (serotonin I and serotonin II) (Isbister and Buckley 2005; Watts 2005).

Epinephrine is a sympathomimetic agent which has an effect on vasoconstriction, and bronchodilation. It also reduces mucosal edema. Epinephrine down-regulates histamine released from mast-cells and other mediators of inflammation. It is an optional drug for the treatment of anaphylaxis and should be injected promptly in the event of an anaphylactic reaction or when progression to anaphylaxis is likely to occur (Järvinen and Celestin 2014).

The differential diagnosis of anaphylaxis includes several medical diseases and somatoform disorders, which affect the organ systems most frequently involved in anaphylaxis (Muraro et al. 2014). Patients having anxiety and/or panic disorder had already been excluded from this study. No psychiatric pathology had been observed in study patients. All of our patients, except for one who had immunotherapy, had received their injections several times without experiencing any allergic reaction before the occurrence of a hypertensive anaphylactic reaction.

Allergen immunotherapy has been shown to be an effective treatment for respiratory allergies and hymenoptera venom allergy. The major risk of an immunotherapy, especially with the venom, is anaphylaxis, with an incidence of up to 12 % for hymenoptera venom (Lockey et al. 1990). It is expected to have more adverse effects on ultra-rush (few hours) compared to a rush protocol, and with rush compared to cluster protocols. In general, although there are commercial preparations used for skin tests, in the event that no commercial preparations containing the suspected allergen can be found or that the level of the allergen is thought to be quite low, it is possible to directly perform skin testings by diluting the food as it is consumed or through its juice (prick to prick test), and in this case, allergic reactions due to the non-standardized allergen may rarely occur (Bernstein et al. 2008). The risk of generalized allergic reactions to skin prick testing may be higher in poly-sensitized individuals and in those who underwent skin prick testing with multiple fresh foods.

Anaphylactic reactions have been associated with monoclonal antibodies and biological modifiers and risk of anaphylaxis with omalizumab is reported to be 0.2 % (Järvinen and Celestin 2014). In our study, the risk of anaphylaxis development with the administration of omalizumab was found to be 0.21 %, and that was a HA. In the literature, a severe anaphylaxis with hypertension after applying oxaliplatin (alkylating chemotherapeutic agent) was reported in two cases (Lee et al. 2007).

We assume that in minority of patients, early compensatory vasopressor response may be dominant, which can cause anaphylactic reactions manifesting with hypertensive attacks. Especially, in young patients, the possibility of a hypertensive attack in anaphylactic reactions should be kept in mind, and the arterial blood pressure should be measured prior to the epinephrine injection to avoid a potential dangerous side effect of epinephrine (Wendt et al. 2011). There is no information in the literature regarding rates of hypertensive anaphylactic reactions. We think that this is due to insufficient evidence of hypertension during the course of an acute anaphylactic reaction which is also perplexed by prompt administration of epinephrine in order to prevent potential life-threatening reactions like upper airway obstruction.

In conclusion, even though a hypertensive attack may occur in few of anaphylaxis patients, there must be no hesitation for using epinephrine during the potential life-threatening manifestations of anaphylaxis, such as upper airway obstruction. Anaphylaxis and hypertension can be recovered by epinephrine injection when required. According to the best of our knowledge, this study is the first original study about the prevalence of HA in English-medical literature.

Abbreviations

BP: 

blood pressure

EAACI: 

the European Academy of Allergy and Clinical Immunology

GATA: 

Gulhane Military Medical Academy

HA: 

hypertensive anaphylaxis

IT: 

immunotherapy

HDM: 

house dust mite

Declarations

Authors’ contributions

ES, AK, SO contributed to the study design; VO, IC, EK, EK contributed to data collection; VO, IC, OS and MS contributed to data interpretation; ES, EK contributed for writedown of the manuscript. AK, SO contributed to the critical review. ES, AK, SD, VO, IC, EK, SO were employee of GATA Haydarpasa Training Hospital and EK was employee of Kasimpasa Military Hospital at the time of the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All authors had full access to all of the data in this study and take complete responsibility for the integrity and accuracy of the data and we agree to allow the journal to review our data if requested.

Ethics approval and consent to participate

The study was Institutional review board-approved and registered (GATA Haydarpasa Training Hospital, Ethical Comittee, Istanbul/TURKEY; 26/03/2015—1491-43-15/1539). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Our study was designed to observe on outpatient treatment and diagnostic process. Patient participation and all treatment and diagnostic procedures was carried with patients written consents.

Funding

No funding or sponsorship was received for this study or publication of this article. Article processing charges payed by authors.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Internal Medicine, GATA Haydarpasa Training Hospital
(2)
Department of Allergy and Immunology, GATA Haydarpasa Training Hospital
(3)
Department of Otolaryngology, GATA Haydarpasa Training Hospital
(4)
Department of Internal Medicine, Hakkari Military Hospital
(5)
Department of Rheumatology, GATA Gulhane Military Medical Academy
(6)
Department of Microbiology and Clinical Microbiology, GATA Haydarpasa Training Hospital
(7)
Department of Chest Disease, Kasimpasa Military Hospital
(8)
Department of Dermatology, GATA Haydarpasa Training Hospital

References

  1. Bernstein IL, Li JT, Bernstein DI et al (2008) Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 100:S1–S148. doi:10.1016/S1081-1206(10)60305-5 View ArticleGoogle Scholar
  2. Ecc Committee S, Task Forces of the American Heart A (2005) Part 1: introduction. Circulation 112:IV1–IV203. doi:10.1016/j.resuscitation.2005.09.010
  3. Isbister GK, Buckley NA (2005) The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 28:205–214. doi:10.1097/01.wnf.0000177642.89888.85 View ArticleGoogle Scholar
  4. James PA, Oparil S, Carter BL et al (2013) Evidence-based guideline for the management of high blood pressure in adults. JAMA 1097:1–14. doi:10.1001/jama.2013.284427 Google Scholar
  5. Järvinen KM, Celestin J (2014) Anaphylaxis avoidance and management: educating patients and their caregivers. J Asthma Allergy 7:95–104. doi:10.2147/JAA.S48611 View ArticleGoogle Scholar
  6. Lee MY, Yang MH, Liu JH et al (2007) Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 15:89–93. doi:10.1007/s00520-006-0107-9 View ArticleGoogle Scholar
  7. Lockey RF, Turkeltaub PC, Olive ES et al (1990) The hymenoptera venom study III: safety of venom immunotherapy. J Allergy Clin Immunol 86:775–780. doi:10.1016/S0091-6749(05)80182-4 View ArticleGoogle Scholar
  8. Muraro A, Roberts G, Worm M et al (2014) Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy Eur J Allergy Clin Immunol 69:1026–1045. doi:10.1111/all.12437 View ArticleGoogle Scholar
  9. Sampson HA, Muñoz-Furlong A, Campbell RL et al (2006) Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 47:373–380. doi:10.1016/j.annemergmed.2006.01.018 View ArticleGoogle Scholar
  10. Simons FER (2010) World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy–immunology specialists in health care settings. Ann Allergy Asthma Immunol 104:405–412. doi:10.1016/j.anai.2010.01.023 View ArticleGoogle Scholar
  11. Simons FER, Ardusso LRF, Bilò MB et al (2012) 2012 Update. Curr Opin Allergy Clin Immunol 12:389–399. doi:10.1097/ACI.0b013e328355b7e4 View ArticleGoogle Scholar
  12. Watts SW (2005) 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci 108:399–412. doi:10.1042/CS20040364 View ArticleGoogle Scholar
  13. Wendt M, Audebert H, Nolte CH (2011) Intracerebral hemorrhage following epinephrine application for anaphylactic reaction. Clin Neurol Neurosurg 113:699–700. doi:10.1016/j.clineuro.2011.03.014 View ArticleGoogle Scholar

Copyright

© The Author(s) 2016